Iran and the Nuclear Threat: A Question of Fact Versus Fear
Iran Second Pieter Lamper Iran Second Pieter Lamper

Iran and the Nuclear Threat: A Question of Fact Versus Fear

The discussion surrounding Iran and its nuclear capabilities often centers on the misconception that it poses a nuclear threat to global security. However, investigations by bodies like the International Atomic Energy Agency (IAEA) indicate that Iran does not possess nuclear weapons and has solely developed nuclear technology for peaceful purposes. In contrast, significant nuclear threats are evident from the nine countries—such as the United States and Russia—that hold the vast majority of the world's nuclear arsenals, with over 90% of warheads owned by these two nations. Historical patterns show that nuclear-armed states engage in military interventions more frequently than Iran, which has maintained a comparatively restrained military record. These states justify their arsenals as essential for national security, while Iran claims its nuclear activities are peaceful and comply with the Non-Proliferation Treaty (NPT). To address the irrationality of sanctions based on fear rather than facts, a fair approach would hold all nations to the same standards regarding nuclear nonproliferation. Disarmament efforts must take into account actual threats rather than hypothetical scenarios, emphasizing equality in international relations and consistent accountability for all states.

Read More
Legal Restrictions on mRNA Vaccine Release Pre-Pandemic
Project Lightspeed Pieter Lamper Project Lightspeed Pieter Lamper

Legal Restrictions on mRNA Vaccine Release Pre-Pandemic

Before the COVID-19 pandemic, mRNA vaccine technology was extensively researched but legally restricted from public release due to stringent regulatory frameworks. These laws mandated that vaccines undergo comprehensive, multi-year evaluations—including preclinical studies and three phases of human trials—before being licensed for use, prioritizing public safety by ensuring thorough assessments of safety and efficacy. During the pandemic, however, traditional regulatory safeguards were temporarily bypassed through Emergency Use Authorizations (EUAs), allowing for the expedited deployment of COVID-19 mRNA vaccines from companies like BioNTech/Pfizer and Moderna. This meant that these vaccines entered the market without the standard two-year clinical follow-up and extensive testing, as trials were compressed and overlapped due to the urgent need. As a consequence, official long-term safety and effectiveness data for these vaccines became available only years later, with BioNTech's Comirnaty vaccine releasing its results in 2024, reflecting the rigorous standards of traditional vaccine testing. This provided a stark contrast to preliminary results released in 2020, which were based on limited observation and smaller sample sizes.

Read More